Targeting severe symptoms of early 2023-new outbreak of COVID-19 by classical drug dexamethasone: a potential fatality reducing agent

J Transl Med. 2023 May 26;21(1):348. doi: 10.1186/s12967-023-04186-4.

Authors

Dongsheng Liu^#¹, Aamir Saeed^#², Sidra Majaz², Bashrat Ahmad², Ashfaq Ahmad³, Yingqiu Xie⁴

Affiliations

¹ Shandong First Medical University, Jinan, China.
² Department of Bioinformatics, Hazara University, Mansehra, 21300, KPK, Pakistan.
³ Department of Bioinformatics, Hazara University, Mansehra, 21300, KPK, Pakistan. ashfaq.binfo@hu.edu.pk.
⁴ Department of Biology, School of Sciences and Humanities, Nazarbayev University, Astana, 010000, Kazakhstan. yingqiu.xie@nu.edu.kz.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Drug Treatment
COVID-19*
Dexamethasone / pharmacology
Dexamethasone / therapeutic use
Disease Outbreaks
Humans
Reducing Agents

Substances

Reducing Agents
Dexamethasone